471 results on '"Pircher, Andreas"'
Search Results
2. Cholecystokinin-2 receptor targeting by [68Ga]Ga-DOTA-MGS5 PET/CT in a patient with extensive disease small cell lung cancer
3. Lipid nanoparticles in the treatment of lung cancer—hype or hope?
4. Rare lung cancer special: a multifaceted approach
5. The multivisceral landscape of colorectal cancer metastasis: implications for targeted therapies
6. Beyond binary: bridging neutrophil diversity to new therapeutic approaches in NSCLC
7. Comparative analysis of 10X Chromium vs. BD Rhapsody whole transcriptome single-cell sequencing technologies in complex human tissues
8. The LARP1 homolog Slr1p controls the stability and expression of proto-5′TOP mRNAs in fission yeast
9. “Navigating the evolving landscape of cancer treatment: a triad of progress”
10. Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer
11. Molecular profiling in lung cancer
12. Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature
13. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer
14. Comprehensive characterization of the prostate tumor microenvironment identifies CXCR4/CXCL12 crosstalk as a novel antiangiogenic therapeutic target in prostate cancer
15. Rare lung cancers—Primary pulmonary leiomyosarcoma: A case report
16. Targeting metabolic dependencies in JAK2-V617F–driven MPNs
17. Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis
18. The impact and relevance of techniques and fluids on lung injury in machine perfusion of lungs
19. Case report: Dissolving carotid plaque associated to Lorlatinib-related dyslipidemia
20. Intravenous iron-induced hypophosphatemia and kidney stone disease
21. A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy?
22. Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition
23. Death of unknown cause? Post-mortem diagnosis of fulminant course of an EBV-associated secondary hemophagocytic lymphohistiocytosis
24. ASCO 2021—selection of personal highlights in early stage non-small cell lung cancer
25. Breast implant-associated anaplastic large-cell lymphoma—update on challenges, advances and opportunities
26. ASCO 2020 non-small lung cancer (NSCLC) personal highlights
27. Cytotoxics and Anti-angiogenics: Metronomic Therapies
28. Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)
29. Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis
30. ESMO 2019—personal non-small lung cancer highlights
31. BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials
32. Evidence-based follow-up in lung cancer?: Focusing on the risk group of recently operated patients
33. Rare lung cancers—2021 update on challenges, advances, and opportunities
34. Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts
35. Whole stromal fibroblast signature is linked to specific chemokine and immune infiltration patterns and to improved survival in NSCLC
36. Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy
37. Serine Synthesis via PHGDH Is Essential for Heme Production in Endothelial Cells
38. Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients
39. ESMO 2018—personal highlights
40. ASCO 2018 NSCLC highlights—combination therapy is key
41. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook
42. Pembrolizumab in mCRPC – Combination therapies as breakthrough to success?
43. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019
44. Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019
45. Phenotype molding of stromal cells in the lung tumor microenvironment
46. Supplementary Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
47. Supplementary Figure from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
48. Supplementary Table from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
49. Data from Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
50. Tissue iron distribution in patients with anemia of inflammation: Results of a pilot study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.